CLSA announces a major expansion to its advocacy team, hiring three new government relations directors based in its Sacramento and Washington, D.C. offices, bringing its in-house advocacy staff count to 9 personnel. Oliver Rocroi has been hired as Senior Director, State Government Relations; Manny Heer has been hired as Director, Alliance Development & Advocacy; and Adam Lotspike has been hired as Associate Director, Federal Government Relations.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Jose Mercury News calling on Congress to repeal the Independent Payment Advisory Board (IPAB), a controversial advisory board enacted as part of the ACA, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development.
On March 16, the President released his budget blueprint for fiscal year (FY) 2018, which proposes deep cuts in funding for federal research at the NIH as well as an increase in FDA user fees.
Leadership of federal departments and agencies with oversight of issues of importance to California’s life sciences sector continue to take shape under the new Trump Administration.
CLSA President & CEO Sara Radcliffe comments on the President’s proposed $6 billion cut to the National Institutes of Health (NIH) in his budget blueprint.
CLSA President & CEO Sara Radcliffe reacts to the President’s proposed $6 billion cut to the NIH’s budget in this San Diego Union-Tribune article.
CLSA’s Jenny Carey and EveryLife Foundation for Rare Diseases’ Julia Jenkins pen an op-ed in The Hill on the need enact sound public policies that help tackle the more than 7,000 rare diseases affecting 30 million people, more than half of whom are children.
On Feb. 16, House Republican leadership distributed a policy brief outlining how they intend to go about repealing and replacing the Patient Protection and Affordable Care Act (ACA) originally enacted in 2010.
Given the medical device excise tax’s disproportionate impact in California, CLSA has been a leading advocate in support of its full repeal. In the 115th Congress, CLSA continues to advocate for a full and permanent repeal of the medical device excise tax.
View CLSA’s 2017 Federal Policy & Advocacy Agenda, to guide our priority policy and advocacy issues, and related education and outreach opportunities.